ATE409481T1 - Verwendung von 3,11b-cis-dihydrotetrabenazin zur behandlung von symptomen der huntington-krankheit - Google Patents

Verwendung von 3,11b-cis-dihydrotetrabenazin zur behandlung von symptomen der huntington-krankheit

Info

Publication number
ATE409481T1
ATE409481T1 AT06764942T AT06764942T ATE409481T1 AT E409481 T1 ATE409481 T1 AT E409481T1 AT 06764942 T AT06764942 T AT 06764942T AT 06764942 T AT06764942 T AT 06764942T AT E409481 T1 ATE409481 T1 AT E409481T1
Authority
AT
Austria
Prior art keywords
dihydrotetrabenazine
huntington
cis
disease
treat symptoms
Prior art date
Application number
AT06764942T
Other languages
English (en)
Inventor
Robert Tridgett
T Filloux
Original Assignee
Cambridge Lab Ireland Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cambridge Lab Ireland Ltd filed Critical Cambridge Lab Ireland Ltd
Application granted granted Critical
Publication of ATE409481T1 publication Critical patent/ATE409481T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT06764942T 2005-07-14 2006-07-13 Verwendung von 3,11b-cis-dihydrotetrabenazin zur behandlung von symptomen der huntington-krankheit ATE409481T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0514501.6A GB0514501D0 (en) 2005-07-14 2005-07-14 Pharmaceutical compounds

Publications (1)

Publication Number Publication Date
ATE409481T1 true ATE409481T1 (de) 2008-10-15

Family

ID=34897233

Family Applications (2)

Application Number Title Priority Date Filing Date
AT06764942T ATE409481T1 (de) 2005-07-14 2006-07-13 Verwendung von 3,11b-cis-dihydrotetrabenazin zur behandlung von symptomen der huntington-krankheit
AT08017191T ATE522215T1 (de) 2005-07-14 2006-07-13 Verwendung von 3,11b-cis-dihydrotetrabenazine zur behandlung von symptomen von huntington-chorea

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT08017191T ATE522215T1 (de) 2005-07-14 2006-07-13 Verwendung von 3,11b-cis-dihydrotetrabenazine zur behandlung von symptomen von huntington-chorea

Country Status (24)

Country Link
US (1) US20080319000A1 (de)
EP (2) EP1885363B1 (de)
JP (1) JP2009501202A (de)
KR (1) KR20080030666A (de)
CN (1) CN101282726A (de)
AT (2) ATE409481T1 (de)
AU (1) AU2006268098B2 (de)
CA (1) CA2615077A1 (de)
CY (1) CY1108653T1 (de)
DE (1) DE602006002982D1 (de)
DK (1) DK1885363T3 (de)
ES (1) ES2314931T3 (de)
GB (1) GB0514501D0 (de)
HK (1) HK1111085A1 (de)
HR (1) HRP20080677T3 (de)
ME (1) ME01629B (de)
NZ (1) NZ565522A (de)
PL (1) PL1885363T3 (de)
PT (1) PT1885363E (de)
RS (1) RS50626B (de)
RU (1) RU2409365C2 (de)
SI (1) SI1885363T1 (de)
WO (1) WO2007007105A1 (de)
ZA (1) ZA200800905B (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2410947B (en) * 2004-02-11 2008-09-17 Cambridge Lab Ltd Pharmaceutical compounds
GB0516168D0 (en) * 2005-08-05 2005-09-14 Cambridge Lab Ireland Ltd Pharmaceutical compounds
PT2081929E (pt) 2006-11-08 2013-04-15 Neurocrine Biosciences Inc Compostos de 3-isobutil-9,10-dimetoxi- 1,3,4,6,7,11b-hexahidro-2h-pirido[2,1-a]isoquinolin- 2-ol substituídos e métodos com estes relacionados
GB0810857D0 (en) * 2008-06-13 2008-07-23 Cambridge Lab Ireland Ltd Pharmaceutical compounds
GB2462611A (en) * 2008-08-12 2010-02-17 Cambridge Lab Pharmaceutical composition comprising tetrabenazine
US20110053866A1 (en) * 2008-08-12 2011-03-03 Biovail Laboratories International (Barbados) S.R.L. Pharmaceutical compositions
US20120208773A1 (en) * 2008-08-12 2012-08-16 Valeant International (Barbados) Srl Pharmaceutical compositions with tetrabenazine
GB2463451A (en) * 2008-09-08 2010-03-17 Cambridge Lab 3, 11b cis-dihydrotetrabenazine compounds for use in the treatment of dementia
GB2463452A (en) * 2008-09-08 2010-03-17 Cambridge Lab Desmethyl derivatives of tetrabenazine and pharmaceutical compositions thereof
GB2463283A (en) * 2008-09-08 2010-03-10 Cambridge Lab 3,11b-cis-dihydrotetrabenazine for use in treating asthma
CA2771539A1 (en) * 2009-08-12 2011-02-17 Valeant International (Barbados) Srl Pharmaceutical compositions with tetrabenzine
WO2011153157A2 (en) * 2010-06-01 2011-12-08 Auspex Pharmaceutical, Inc. Benzoquinolone inhibitors of vmat2
WO2012095548A2 (es) 2011-01-13 2012-07-19 Centro De Investigación Biomédica En Red De Enfermedades Neurodegenerativas (Ciberned) Compuestos para el tratamiento de enfermedades neurodegenerativas
GB201705303D0 (en) 2017-04-01 2017-05-17 Adeptio Pharmaceuticals Ltd Pharmaceutical compositions
GB201705306D0 (en) 2017-04-01 2017-05-17 Adeptio Pharmaceuticals Ltd Pharmaceutical compositions
EP3606530A2 (de) * 2017-04-01 2020-02-12 Adeptio Pharmaceuticals Limited Dihydrotetrabenazin zur verwendung bei der behandlung einer bewegungsstörung
GB201705302D0 (en) 2017-04-01 2017-05-17 Adeptio Pharmaceuticals Ltd Pharmaceutical compositions
GB201705304D0 (en) 2017-04-01 2017-05-17 Adeptio Pharmaceuticals Ltd Pharmaceutical compositions
GB201808464D0 (en) * 2018-05-23 2018-07-11 Adeptio Pharmaceuticals Ltd Pharmaceutical compounds for use in treating huntington's disease
JP2022541021A (ja) * 2019-07-16 2022-09-21 ラッシュ・ユニバーシティ・メディカル・センター 神経変性障害を治療するためのベンゾエート含有組成物の使用

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3132147A (en) * 1964-05-05
US2954382A (en) * 1960-09-27 Xpreparation of hexahydrobenzoquinol-
US3009918A (en) * 1961-11-21 Chz ch
US3159638A (en) * 1964-12-01 Xcha-chj
US3053845A (en) * 1962-09-11 Benzofykedocolines
US3314966A (en) * 1967-04-18 Substituted benzo[a]quinolizines
US3095419A (en) * 1963-06-25 Process for preparing z-oxo-j-
US2830993A (en) * 1958-04-15 Quinolizine derivatives
US3123609A (en) * 1964-03-03 Benzo
US3209005A (en) * 1965-09-28 Hexahydro-llbh-benzo[a] quinolizines and processes therefor
US2843591A (en) * 1958-07-15 Method for preparing same
US3079395A (en) * 1963-02-26 Novel z-oxq-benzoquinoliaine
US3045021A (en) * 1959-09-24 1962-07-17 Hoffmann La Roche Preparation of substituted 2-oxobenzoquinolizines
GB999092A (en) * 1959-11-24 1965-07-21 Wellcome Found Method for making benzo(a)-quinolizine derivatives
US3375254A (en) * 1961-09-29 1968-03-26 Burroughs Wellcome Co Manufacture of 1, 2, 3, 4, 6, 7-hexahydro-2-oxo-11bh-benzo(a)quinolizines
US3105079A (en) * 1961-12-29 1963-09-24 Pfizer & Co C 10-aminobenzopyridocolines
US3390152A (en) * 1965-10-21 1968-06-25 Abbott Lab 9, 10-alkoxy-3-alkyl-2, 2-(dithiosubstituted)-benzoquinolizines
JPS4836303B1 (de) * 1968-12-27 1973-11-02
US3635986A (en) * 1969-12-22 1972-01-18 Miles Lab 2-substituted amino-hexahydrobenzo(a)quinolizines
YU264675A (en) * 1974-10-23 1982-05-31 Chinoin Gyogyszer Es Vegyeszet Process for obtaining benzo (a)-quinolizidine derivatives
GB1513824A (en) * 1975-05-22 1978-06-14 Wyeth John & Brother Ltd 1,3,4,6,7,11b-hexahydro-2h-benzo(a)quinolizine derivative
US4133812A (en) * 1975-11-21 1979-01-09 Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara Rt. Process for producing benzo (a) quinolizine derivatives
US4304913A (en) * 1978-11-20 1981-12-08 Miles Laboratories, Inc. Trans-2-substituted-amido-hexahydrobenzo [A]quinolizines
US4353656A (en) * 1980-10-14 1982-10-12 Xerox Corporation Moving coil, multiple energy print hammer system including a closed loop servo
US4778054A (en) * 1982-10-08 1988-10-18 Glaxo Group Limited Pack for administering medicaments to patients
US4811731A (en) * 1985-07-30 1989-03-14 Glaxo Group Limited Devices for administering medicaments to patients
GB9004781D0 (en) * 1990-03-02 1990-04-25 Glaxo Group Ltd Device
US6087376A (en) * 1997-02-05 2000-07-11 University Of Kentucky Research Foundation Use of lobeline compounds in the treatment of central nervous system diseases and pathologies
FR2794742B1 (fr) * 1999-06-11 2005-06-03 Sanofi Synthelabo Nouveaux derives du benzene, un procede pour leur preparation et les compositions pharmaceutiques les contenant
US6632666B2 (en) * 2000-01-14 2003-10-14 Biolife Solutions, Inc. Normothermic, hypothermic and cryopreservation maintenance and storage of cells, tissues and organs in gel-based media
WO2001079198A1 (en) * 2000-04-18 2001-10-25 Agouron Pharmaceuticals, Inc. Pyrazoles for inhibiting protein kinase
CA2673334C (en) * 2003-06-16 2013-11-12 Andrx Pharmaceuticals, Llc Oral extended-release composition
GB2410947B (en) * 2004-02-11 2008-09-17 Cambridge Lab Ltd Pharmaceutical compounds
WO2006053067A2 (en) * 2004-11-09 2006-05-18 Prestwick Pharmaceuticals, Inc. Combination of amantadine and a tetrabenazine compound for treating hyperkinetic disorders
KR100682506B1 (ko) * 2005-01-18 2007-02-15 (주)젠크로스 프라지콴텔, 또는 이의 염을 포함하는 약학 조성물
GB0516168D0 (en) * 2005-08-05 2005-09-14 Cambridge Lab Ireland Ltd Pharmaceutical compounds
US20110053866A1 (en) * 2008-08-12 2011-03-03 Biovail Laboratories International (Barbados) S.R.L. Pharmaceutical compositions
GB2462611A (en) * 2008-08-12 2010-02-17 Cambridge Lab Pharmaceutical composition comprising tetrabenazine
GB2463452A (en) * 2008-09-08 2010-03-17 Cambridge Lab Desmethyl derivatives of tetrabenazine and pharmaceutical compositions thereof
GB2463283A (en) * 2008-09-08 2010-03-10 Cambridge Lab 3,11b-cis-dihydrotetrabenazine for use in treating asthma
GB2463451A (en) * 2008-09-08 2010-03-17 Cambridge Lab 3, 11b cis-dihydrotetrabenazine compounds for use in the treatment of dementia

Also Published As

Publication number Publication date
ES2314931T3 (es) 2009-03-16
US20080319000A1 (en) 2008-12-25
PT1885363E (pt) 2009-01-08
NZ565522A (en) 2010-04-30
EP2027861A1 (de) 2009-02-25
RS50626B (sr) 2010-06-30
ATE522215T1 (de) 2011-09-15
DE602006002982D1 (de) 2008-11-13
JP2009501202A (ja) 2009-01-15
KR20080030666A (ko) 2008-04-04
EP1885363B1 (de) 2008-10-01
CY1108653T1 (el) 2014-04-09
RU2008105590A (ru) 2009-08-20
SI1885363T1 (sl) 2009-02-28
RU2409365C2 (ru) 2011-01-20
CA2615077A1 (en) 2007-01-18
GB0514501D0 (en) 2005-08-24
CN101282726A (zh) 2008-10-08
PL1885363T3 (pl) 2009-05-29
WO2007007105A1 (en) 2007-01-18
HRP20080677T3 (en) 2009-02-28
AU2006268098B2 (en) 2011-02-17
ZA200800905B (en) 2010-04-28
EP2027861B1 (de) 2011-08-31
EP1885363A1 (de) 2008-02-13
AU2006268098A1 (en) 2007-01-18
ME01629B (me) 2010-06-30
HK1111085A1 (en) 2008-08-01
DK1885363T3 (da) 2008-12-08

Similar Documents

Publication Publication Date Title
ATE409481T1 (de) Verwendung von 3,11b-cis-dihydrotetrabenazin zur behandlung von symptomen der huntington-krankheit
EA200970575A1 (ru) Соединения на основе 4-фенил-6-(2,2,2-трифтор-1-фенилэтокси)пиримидина и способы их применения
ATE534391T1 (de) 3,11b-cis-dihydrotetrabenazin zur behandlung von psychosen
BRPI0508051A (pt) derivados de heteroarilaminopirazol utilizáveis para o tratamento de diabetes
BRPI0515549A (pt) compostos, composições e métodos de inibição de toxicidade de alfa-sinucleìna
ATE521608T1 (de) Glucokinaseaktivatoren
DK2194053T3 (da) Methoxypiperidinderivater til brug i behandling af gastrointestinale forstyrrelser og forstyrrelser i centralnervesystemet.
ATE494890T1 (de) Alpha-aminoamid-derivate zur behandlung von suchtstörungen
DE602004020072D1 (de) 1,2,3,4-tetrasubstituiertes indol zur behandlung von atemwegserkrankungen
ATE446102T1 (de) Behandlung von gewichtsverlust bei patienten mit entzündlichen darmerkrankungen mittels s. boulardii
ATE434451T1 (de) Calciumphosphat materialien mit verbesserter osteoinduktivität
DE502006007982D1 (de) Neue arzneimittelkombinationen zur behandlung von atemwegserkrankungen
DE502004006619D1 (de) Substituierte 2-aminotetraline zur vorbeugenden behandlung von morbus parkinson
WO2007058805A3 (en) Compositions and methods for treating cns disorders
ATE510536T1 (de) Verwendung von 2,5-dihydroxybenzol-derivaten zur behandlung von reaktiven gewebeerkrankungen
NO20076405L (no) Anvendelse av 24-nor-UDCA
BRPI0517972A (pt) ácido 5,6,7-triidroxiheptanóico e análogos para o tratamento de doenças oculares e doenças associadas com respostas hiperproliferativas e angiogênicas
ATE494008T1 (de) Verwendung eines p38-kinasehemmers zur behandlung von psychiatrischen erkrankungen
DE602005018179D1 (de) Behandlung von krankheiten
ATE478707T1 (de) Kim-1-antikörper zur behandlung von th2- vermittelten erkrankungen
ATE394122T1 (de) Hemmung des cd95 liganden/rezeptor-systems zur behandlung von neurologischen erkrankungen und verletzungen
ATE374202T1 (de) Neue analoga von nitrobenzylthioinosin
DE60219495D1 (de) Verwendung von Interleukin-18 zur Behandlung von UV-assoziierten Hautkrankheiten
ATE473737T1 (de) Verwendung von 2,3-dehydronaringenin-derivaten zur behandlung von entzündungsprozessen und diese derivate enthaltende pharmazeutische zusammensetzung
ATE543510T1 (de) Bowman-birk-hemmer-zusammensetzungen zur behandlung von muskelatrophie und degenerativer muskelerkrankung

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1885363

Country of ref document: EP